Patent: 10,507,262
Summary for Patent: 10,507,262
| Title: | Biocompatible hydrogel treatments for retinal detachment |
| Abstract: | Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch. |
| Inventor(s): | Askari; Syed H. (San Jose, CA), Choi; Yeon S. (Emeryville, CA) |
| Assignee: | C.P. MEDICAL CORPORATION (Norcross, GA) |
| Application Number: | 15/467,019 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,507,262
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | 10,507,262 | 2037-03-23 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | December 10, 1997 | 10,507,262 | 2037-03-23 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | May 12, 1998 | 10,507,262 | 2037-03-23 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | January 2, 2003 | 10,507,262 | 2037-03-23 |
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | August 24, 1998 | 10,507,262 | 2037-03-23 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | November 2, 1998 | 10,507,262 | 2037-03-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
